Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 1999
[Comparative pharmacokinetic study of two different ways of using L-asparaginase as the main drug in combination chemotherapy].
Клиническое исследованиеСравнительное исследованиеАннотация на английскомСтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Y, Jiang H, Xie X
Аннотация
OBJECTIVE: To search for a safer and more effective way of using L-asparaginase as the main drug in combination protocol.
METHOD: Twenty children with lymphoid malignancies were randomly divided into two groups: Group A and Group B, for L-asparaginase therapy. Group A: Leunase 6,000 KU/m2, continuous intravenous injection every day for 8 times; Group B: Leunase 6,000 KU/m2, continuous intravenous injection every other day for 8 times. Blood samples were collected every day for group A and every other day for group B and serum L-asparaginase and L-asparagine levels were tested.
RESULTS: 1. The pre-treatment mean value of serum L-asparaginase in group A was significantly higher than that in group B (P < 0.01). The levels of L-asparaginase in group A tended to increase day by day during the therapeutic course while those in group B without increasing tendency. 2. The L-asparagine levels and their dynamic changes were not significantly different between the two groups (P > 0.05).
CONCLUSION: The administration of Leunase by continuous intravenous injection every other day is a much safer and effective protocol and worthy of recommendation.
METHOD: Twenty children with lymphoid malignancies were randomly divided into two groups: Group A and Group B, for L-asparaginase therapy. Group A: Leunase 6,000 KU/m2, continuous intravenous injection every day for 8 times; Group B: Leunase 6,000 KU/m2, continuous intravenous injection every other day for 8 times. Blood samples were collected every day for group A and every other day for group B and serum L-asparaginase and L-asparagine levels were tested.
RESULTS: 1. The pre-treatment mean value of serum L-asparaginase in group A was significantly higher than that in group B (P < 0.01). The levels of L-asparaginase in group A tended to increase day by day during the therapeutic course while those in group B without increasing tendency. 2. The L-asparagine levels and their dynamic changes were not significantly different between the two groups (P > 0.05).
CONCLUSION: The administration of Leunase by continuous intravenous injection every other day is a much safer and effective protocol and worthy of recommendation.